Sutro Biopharma — Third Quarter 2026 Earnings Summary

Sutro Biopharma reported third-quarter 2026 financial results showing $9.1 million in revenue and a net loss of $31.5 million, while maintaining a cash balance of $142.2 million expected to fund operations through the first half of 2028. The company advanced its STRO-004 ADC program with encouraging early clinical data and initiated dosing for the STRO-006 ITGB6-targeting ADC, with both programs scheduled for further clinical updates in 2027. Additionally, the STRO-227 dual-payload ADC is set to enter clinical trials in early 2027, and a collaboration with Astellas triggered a $10 million milestone payment following the dosing of a second dual-payload program.